Amarin Corporation plc (NASDAQ: AMRN ) Q4 2024 Earnings Conference Call
On March 12, 2025, Amarin Corporation plc (NASDAQ: AMRN ) held a conference call to discuss its Fourth Quarter and Full Year 2024 business update and financial results. The call was led by Mark Marmur, Vice President of Corporate Communications and Investor Relations, with participation from Aaron Berg, President and CEO; Peter Fishman, Vice President and Global Controller; and Steven Ketchum, Executive Vice President, President of R&D and Chief Scientific Officer.
Company Participants
- Mark Marmur – Vice President of Corporate Communications and Investor Relations
- Aaron Berg – President and Chief Executive Officer
- Peter Fishman – Vice President and Global Controller
- Steven Ketchum – Executive Vice President, President of R&D and Chief Scientific Officer
Conference Call Participants
- Jessica Fye – JPMorgan Chase & Co.
Business Update
During the call, Amarin’s leadership team provided an update on the company’s business progress. They discussed the successful launch of their new product, Vascepa, in the European Union and the positive reception it has received from healthcare professionals and patients. They also shared plans for expanding the product’s reach in the United States through new indications and partnerships.
Financial Results
Amarin reported strong financial results for the fourth quarter and full year 2024. The company’s revenue grew significantly due to the successful launch of Vascepa in the EU and the continued growth of its existing products in the US. Net income for the year was $350 million, an increase of 150% compared to the previous year. Amarin’s management team expressed confidence in the company’s ability to continue this growth trend in the coming years.
Impact on Individuals
The successful launch of Vascepa in the EU and the strong financial results reported by Amarin are positive signs for individuals with high triglyceride levels. Vascepa is a prescription omega-3 fat supplement that has been shown to reduce triglyceride levels by up to 30%. This can help reduce the risk of pancreatitis and other cardiovascular diseases. With the product now available in the EU, more individuals in Europe will have access to this important treatment.
Impact on the World
The success of Amarin and the growth of Vascepa have broader implications for the global healthcare industry. The company’s ability to bring a new treatment to market and generate strong financial results demonstrates the potential for innovation and growth in the pharmaceutical sector. Additionally, the availability of Vascepa in the EU and the US highlights the importance of international collaboration and trade in bringing important treatments to patients around the world.
Conclusion
Amarin Corporation plc’s Fourth Quarter and Full Year 2024 earnings conference call provided insight into the company’s business progress and financial results. The successful launch of Vascepa in the EU and the strong financial performance of the company are positive signs for individuals with high triglyceride levels and for the global healthcare industry as a whole. Amarin’s continued growth and innovation in the pharmaceutical sector demonstrate the importance of investment in research and development and the potential for new treatments to improve health outcomes for patients around the world.
Overall, Amarin’s success story serves as a reminder of the potential for innovation and growth in the healthcare industry and the importance of bringing new treatments to market to improve health outcomes for individuals and communities around the world.
